SCHEMBL1557504

SCHEMBL1557504

COc1[nH]c2ccccc2c1C=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.55
AHR P35869 4/20 0.46
KIF11 P52732 2/20 0.46
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ATM Q13315 1/20 0.42
NR4A2 P43354 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
ABCG2 Q9UNQ0 2/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
PTK2B Q14289 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9669128 0.79 KDM4E (0.49) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL4072427 0.77 KDM4E (0.47) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL14519076 0.77 GSK3B (0.53) KDM4EAHRKIF11MAPTMEN1
SCHEMBL7311550 0.76 KDM4E (0.44) KDM4EKIF11MAPTMEN1KMT2A
SCHEMBL15332438 0.76 PTGS2 (0.58) KDM4EAHRMAPTMEN1KMT2A
SCHEMBL14199367 0.76 AHR (0.43) KDM4EAHRKIF11MAPTMEN1
SCHEMBL1727453 0.76 NPC1 (0.51) KDM4EAHRKIF11MAPTMEN1
SCHEMBL248974 0.76 HPGD (0.61) AHRMAPTMEN1KMT2AALDH1A1
SCHEMBL29378092 0.76 HPGD (0.61) AHRMAPTMEN1KMT2AALDH1A1
SCHEMBL4074976 0.75 ABCG2 (0.49) KDM4EMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458200-B2 Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) 2016-10-04 US disclosed
EP-2303916-B1 METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES HELMHOLTZ INFEKTIONSFORSCHUNG (DE) 2012-05-09 EP disclosed
US-20110311564-A1 Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles GOTTFRIED WILHELM LEIBNIZ UNIVERSITAT HANNOVER (DE) 2011-12-22 US disclosed
EP-2303916-A1 METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2011-04-06 EP disclosed
WO-2010030727-A1 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH LLC (US) 2010-03-18 WO disclosed
WO-2010006682-A1 METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2010-01-21 WO disclosed
EP-2138507-A1 Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2009-12-30 EP disclosed
EP-1943245-A2 1,3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS PLEXXIKON, INC. (US) 2008-07-16 EP disclosed
WO-2007030559-A2 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS PLEXXIKON, INC. (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311564-A1 Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles SKP2, CDKN1A, PSMC1 KDM4E 1695/4885AHR 2280/4885KIF11 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.